nimotuzumab
biocon,daiichi sankyo,oncoscience
['nimotuzumab', 'pancreatic']
#asco survival bump with egfr inhibitor for kras wild-type #pancreaticcancer. one-year survival almost doubled among patients who received anti-egfr mab, and more than four times as many patients in the nimotuzumab group were alive at 3 years. 
Devoted to #endcancer suffering. Scientist, Physician, Educator, Entrepreneur, Advocate. Professor & Past President @MDAndersonNews.  Views expressed are my own